Treatment Information

Back

Breast Cancer treatment details. Chemotherapy.

UCLA Medical Center, Los Angeles, California, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Los Angeles, California
Treatments:ChemotherapyHospital:UCLA Medical Center
Drugs:Journal:Link
Date:Mar 2003

Description:

Patients: This Phase III study involved a total of 429 patients with metastatic breast cancer. Patients were divided into two groups – group 1 comprised 214 patients (213 received treatment); and group 2 comprised was of 215 patients (210 received treatment).

Treatment: Patients in group 1 were administered two chemotherapy drugs – doxorubicin (adriamycin) and docetaxel (taxotere). Patients in group 2 were administered two chemotherapy drugs – doxorubicin (adriamycin) and cyclophosphamide (cytoxan).

Toxicity: One patient in group 1 died from congestive heart failure. Other toxicities included grade 3-4 hematologic toxicity, nausea, vomiting, stomatitis, diarrhea, and asthenia.

Results: Median survival for patients in group 1 was 22.5 months.

Support: The study was supported by Aventis Pharma. Aventis markets taxotere.

Correspondence: Jean-Marc Nabholtz, MD





Back